ROLE OF THE NUCLEAR FACTOR KAPPA B PATHWAY (NF-ΚB)INPOLYCYSTIC OVARY SYNDROME DEVELOPMENT

Authors

  • Husham Ahmed Shaker1, Dr. Rayah Sulaiman Baban2, Dr. Enas Adnan Abdulrasol3 Author

Abstract

Objective: To explore the involvement ofNuclear Factor Kappa Bpathway(NF-κB) in the development of Polycystic ovary syndrome (PCOS) pathogenesis and the possibility of using the parameters of this pathway in the screening and diagnosis of PCOS.Methods:  120women, of which 60 had PCOS and 60 appeared to be healthy. This study was done from January 2022 to December 2023. The average age of participantsranged between18 to 40 years. Age, body mass index (BMI) (kg/m2), fasting glucose, insulin, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), total testosterone, NF-κB,Inhibitor of nuclear factor kappa-B kinase(IKKβ),   interleukin-1 receptor-associated kinase 1(IRAK1),Interleukin 6 (IL-6), Follicle-stimulating hormone (FSH), and luteinizing hormone (LH) were measured for both groups. Results: Serum NF-κB, IKKβ, IRAK1,IL-6,  LH,  FSH, HOMA-IR, and testosterone of PCOS patients were discovered to be remarkably higher than those of the control group, There is no significant difference in age for both groups, while there is a significantly higher in BMI of PCOS compared to controls. A significantpositive correlation was observed between testosterone and NF-κB pathway parameters (NF-κB, IKKβ, IRAK1). Likewise, a strongpositive correlation was detected between serum HOMA-IR and NF-κB pathway parameters. Conclusions: The  NF-κB affects numerousfeatures of PCOS, including hyperandrogenemia and insulin resistance. Inhibition of the NF-κB could be an attractive target for PCOS therapeutic advantage. Indeed, NF-κB, IKKβ, and IRAK1 can be used as new markers for screening and diagnosis of  PCOS.

 

Downloads

Published

2024-01-20

Issue

Section

Articles

How to Cite

ROLE OF THE NUCLEAR FACTOR KAPPA B PATHWAY (NF-ΚB)INPOLYCYSTIC OVARY SYNDROME DEVELOPMENT. (2024). Neuropsychopharmacologia Hungarica, 22(1), 328-341. http://neuropsychopharmacologiahungarica.com/index.php/NPPH/article/view/250